The multifunctional protein DJ-1 facilitates glioblastoma multiforme progression by modulating the UBA52 and NF-κB signaling axis, according to laboratory and animal findings published in Molecular Biology Reports. In evaluating patient tissues, cultured cell lines, and mouse xenografts, investigators determined that DJ-1 depletion substantially suppressed tumor cell proliferation and accelerated apoptosis, while silencing the protein in vivo significantly impeded tumor growth.

Glioblastoma multiforme represents the most lethal and treatment-resistant malignant solid tumor worldwide, where conventional treatments combining surgical resection with chemoradiotherapy continue to produce unsatisfactory clinical outcomes. Although DJ-1 is recognized as a multifunctional protein participating in tumor progression, its precise biological functions and underlying molecular mechanisms in glioblastoma have remained poorly defined, driving the search for novel therapeutic targets.

To assess the clinical relevance of the protein, the researchers analyzed DJ-1 expression profiles using data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases alongside immunohistochemistry and western blot analyses of glioblastoma tissues and cell lines. DJ-1 expression was significantly elevated across the examined glioblastoma tissues and cell cultures, with higher expression levels correlating with unfavorable prognosis in patients.

To investigate functional consequences, the authors constructed a short hairpin RNA targeting DJ-1 (shDJ-1) and transfected it into glioblastoma cell lines. Functional assays demonstrated that DJ-1 knockdown substantially suppressed cell proliferation while promoting apoptosis. Following proteomic sequencing to screen potential downstream effectors of DJ-1, the researchers identified UBA52 as a critical downstream target, subsequently confirming the subcellular co-localization of DJ-1 and UBA52 through immunofluorescence assays.

Mechanistic investigations and western blot analyses revealed that DJ-1 knockdown inactivated the NF-κB signaling pathway by downregulating UBA52. In rescue experiments, overexpressing UBA52 in DJ-1-depleted glioblastoma cells mitigated the tumor-suppressive effects that had been induced by DJ-1 depletion.

The researchers validated these cell culture observations in living systems by establishing a subcutaneous xenograft model in immunodeficient nude mice. In vivo experiments confirmed that silencing DJ-1 significantly impeded tumor growth in the mice. Based on these cellular and animal findings, the study authors conclude that DJ-1 drives glioblastoma progression through the UBA52/NF-κB signaling axis, suggesting that targeting DJ-1 could represent a novel therapeutic strategy for glioblastoma.

By starting with expression profiles from The Cancer Genome Atlas and Genotype-Tissue Expression databases, the investigation established an association between elevated DJ-1 levels and poor clinical prognosis across patient cohorts.

The downstream mechanistic architecture was further clarified through the sequential combination of proteomic screening, subcellular localization, and rescue experiments. The immunofluorescence assays confirmed that DJ-1 and UBA52 share subcellular localization, while the subsequent rescue assays provided critical directional evidence: restoring UBA52 levels counteracted the suppressed proliferation and enhanced apoptosis caused by DJ-1 depletion. Western blot analyses of NF-κB pathway-related proteins confirmed that the inactivation of this downstream cascade stems directly from UBA52 downregulation, identifying a cohesive regulatory chain governing glioblastoma progression.

The in vivo validation was conducted in a subcutaneous xenograft model using immunodeficient nude mice, which demonstrates that DJ-1 silencing impedes solid tumor growth in living host tissue under specific experimental conditions. However, because these findings are derived from cell cultures and immunodeficient animal models rather than clinical human trials, they represent exploratory target identification rather than immediate clinical therapy. Standard clinical care remains centered on surgical resection combined with chemoradiotherapy, underscoring that targeting the DJ-1, UBA52, and NF-κB axis serves as an early-stage therapeutic concept requiring further preclinical evaluation.

Subject of Research: DJ-1 regulation of glioblastoma progression via UBA52 and NF-κB signaling

Article Title: DJ-1 regulates glioblastoma proliferation and apoptosis by modulating UBA52 mediated NF-κB signaling pathway

Article References: Chen, Y., Sun, T., Yin, Z., Lu, X., & Li, Y. (2026). DJ-1 regulates glioblastoma proliferation and apoptosis by modulating UBA52 mediated NF-κB signaling pathway. Molecular Biology Reports, 53(1), Article 1886. https://doi.org/10.1007/s11033-026-13113-x

Image Credits: AI Generated

DOI: 10.1007/s11033-026-13113-x

Keywords: glioblastoma multiforme, DJ-1, UBA52, NF-κB signaling, cell proliferation, apoptosis, xenograft models, oncology, regulates, glioblastoma, proliferation, modulating